ArticleAntimicrobial agents and chemotherapy2019
CTX-M-33, a CTX-M-15 derivative conferring reduced susceptibility to carbapenems.
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Characterization of BAS-1, a novel class A β-lactamase encoded inAntimicrobial agents and chemotherapy · 2026Article
- Characterization of the novel class A β-Lactamase gene blaBMC microbiology · 2026Article
- Carbapenem resistance in aAntimicrobial agents and chemotherapy · 2025Article
- Contributions of β-lactamase substrate specificity and outer membrane permeability to the antibiotic sheltering of β-lactam-susceptible bacteria.RSC chemical biology · 2025Article
- Carbapenem Resistance inMicroorganisms · 2025Review
- Genotyping of extended-spectrum beta-lactamase-producingVeterinary world · 2025Article
- Genomic analysis of non-carbapenem drug-resistant Gram-negative bacteria from advanced chronic liver disease (ACLD) patients suggests no evidence for in-house transmissions.Frontiers in microbiology · 2025Article
- Extended-spectrum β-lactamase- producing gram-negative bacterial infections in severely ill COVID-19 patients admitted in a national referral hospital, Kenya.Annals of clinical microbiology and antimicrobials · 2023Article
- Urban monitoring of antimicrobial resistance during a COVID-19 surge through wastewater surveillance.The Science of the total environment · 2022Article
- Genome-wide identification of carbapenem-resistant Gram-negative bacterial (CR-GNB) isolates retrieved from hospitalized patients in Bihar, India.Scientific reports · 2022Article
- Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Article
- Genome-wide association study ofFrontiers in microbiology · 2022Article
- Intestinal colonization with ESBL-producingFrontiers in public health · 2022Article
- Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection.JAC-antimicrobial resistance · 2021Review
- In Silico Analysis of Extended-Spectrum β-Lactamases in Bacteria.Antibiotics (Basel, Switzerland) · 2021Article
- Carbapenem Use Is Driving the Evolution of Imipenemase 1 Variants.Antimicrobial agents and chemotherapy · 2021Article
- Extended Spectrum Beta-Lactamase (ESBL) Produced by Gram-Negative Bacteria in Trinidad and Tobago.International journal of microbiology · 2021Review
- Prevalence, serotyping and drug susceptibility patterns ofWorld journal of biological chemistry · 2020Article
- Article
- NitroSpeed-Carba NP Test for Rapid Detection and Differentiation between Different Classes of Carbapenemases inJournal of clinical microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CTX-M-type extended-spectrum ß-lactamases (ESBL) are widespread among Enterobacterales worldwide. The most common variant is CTX-M-15 hydrolyzing ceftazidime at high rate, but sparing carbapenems. We identified here CTX-M-33, a point mutant derivative of CTX-M-15 (Asp to Ser substitution at Ambler position 109), exhibiting a low carbapenemase activity. ß-Lactamase CTX-M-33 was identified in a
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.